Abstract 303P
Background
Mandibulectomy typically involves rigid reconstruction using autologous bone and titanium plates. However, in cases with poor performance status or complications as well as the elderly, choosing the optimal surgical method is difficult. For such cases in our hospital, we do not perform rigid reconstruction but opt for only soft tissue reconstruction or primary suturing at the defect site. Here, we retrospectively investigated cases where primary suturing was applied and discuss the utility of the procedure.
Methods
This retrospective study targeted cases of stage T4 lower gingival carcinoma treated with segmental mandibulectomy and primary suturing at the defect site between 1992 and 2018. Survey items were operative time, blood loss volume, perioperative complications, length of hospitalization, and food intake at discharge.
Results
There were 186 cases for which segmental mandibulectomy was performed during the target period, and 13 cases for which primary suturing was also performed. Median operative time was 210 (range, 124-328) min. Median blood loss was 212 (101-867) mL. Six cases had complications during the perioperative period, but in all cases cure was achieved by conservative treatment. Median length of hospitalization was 32 (20-49) days. All cases could tolerate oral intake at discharge.
Conclusions
Segmental mandibulectomy without reconstruction may be a viable surgical option for cases where free tissue reconstruction is not possible.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract